Health · Medical Research · 10 hrs ago
AI-designed virus treatment administered to a patient for the first time
Radical Numerics says it gave a patient AI-designed bacteriophages, viruses that attack bacteria, in what it describes as a first.
The patient had a serious bacterial infection, but the company has not identified the patient or the infection.
The company tested the viruses against bacteria from the patient, and says they eliminated the infection-causing bacteria in laboratory tests.
It says the treatment was given under compassionate use; the company also told Folha that the trial was authorized by the US Food and Drug Administration.
The outcome in the patient has not been disclosed, and the company says results from one person cannot establish whether the treatment is safe or effective.
Phage therapy has been used for more than a century, but finding viruses that target a patient's specific bacteria can take a long time.
AI-designed phages could help target resistant infections, an urgent need as antibiotic resistance grows, but the treatment's results remain unknown.
The company says it intends to publish peer-reviewed research, and any future clinical details depend on appropriate consent.
Radical Numerics says it administered a cocktail of AI-designed bacteriophages to a patient under compassionate use.
The company says the viruses eliminated the patient’s antibiotic-resistant bacterial isolate in laboratory testing, but it has not reported the treatment’s outcome in the patient.
The company says the treatment was authorized by the US Food and Drug Administration, while its technical report has not been peer-reviewed or published in a scientific journal.
The patient’s infection and identity have not been disclosed, and independent experts urged caution about drawing conclusions.
The approach aims to develop phages tailored to bacterial infections, as antibiotic resistance grows worldwide.
- Who
- Radical Numerics developed the bacteriophages and says they were administered to a patient. The patient’s identity and treating doctors were not disclosed.
- What
- An AI-designed bacteriophage cocktail was administered under compassionate use to treat a bacterial infection. The company says it eliminated the patient’s bacterial isolate in laboratory tests.
- When
- The company announced the treatment on Tuesday, October 20, 2026.
- Where
- The patient’s location is not stated. Radical Numerics is based in San Francisco.
- Why
- The phages were intended to target bacteria causing an antibiotic-resistant infection.
Radical Numerics
Independent experts urging caution
Evidence for the treatment
Radical Numerics
The company says the AI-designed phages eliminated the patient’s antibiotic-resistant bacterial isolate in vitro and that the cocktail was administered under compassionate use.
Independent experts urging caution
Experts said it was too early to draw conclusions about whether the treatment worked or how novel the phages were.
Disclosure and research
Radical Numerics
The company cited patient confidentiality and said future clinical details would depend on consent; it said the trial was authorized by the FDA.
Independent experts urging caution
The report has not been peer-reviewed or published in a scientific journal, and experts called for caution.
Researchers at the Arc Institute created an AI model called Evo 2 and tested AI-generated phage genomes.
Radical Numerics presented its Omnii AI model.
Radical Numerics announced that an AI-designed phage cocktail had been administered to a patient.
- Company
- Radical Numerics, based in San Francisco
- AI model
- Omnii-1
- Treatment
- AI-designed bacteriophage cocktail administered under compassionate use
- Laboratory result
- Company says the cocktail eliminated the patient’s bacterial isolate in vitro
- Announcement
- October 20, 2026
- Regulatory status
- Company representatives said the trial received FDA authorization
3 sources
What people are saying
Levamos extremamente a sério nossa responsabilidade de proteger a confidencialidade dos pacientes e preservar a confiança de nossos parceiros clínicos.
Se funcionar, será incrível.
Minha tendência é ser cético.
This marks an important milestone in translating AI-designed biology from computational predictions and laboratory validation to clinical administration